0.044
-0.01 (-17.98%)
| Previous Close | 0.053 |
| Open | 0.052 |
| Volume | 112,368,253 |
| Avg. Volume (3M) | 28,635,067 |
| Market Cap | 265,294 |
| Price / Book | 0.390 |
| 52 Weeks Range | |
| Earnings Date | 19 May 2025 - 22 May 2025 |
| Diluted EPS (TTM) | -8.66 |
| Total Debt/Equity (MRQ) | 3.19% |
| Current Ratio (MRQ) | 1.41 |
| Operating Cash Flow (TTM) | -19.12 M |
| Levered Free Cash Flow (TTM) | -14.10 M |
| Return on Assets (TTM) | -67.48% |
| Return on Equity (TTM) | -182.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | NuCana plc | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -1.00 |
|
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.22% |
| % Held by Institutions | 11.43% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Glass Jacobson Investment Advisors Llc | 31 Mar 2025 | 15,000 |
| Baader Bank Aktiengesellschaft | 31 Mar 2025 | 10,031 |
| Allsquare Wealth Management Llc | 31 Mar 2025 | 205 |
| Activest Wealth Management | 31 Mar 2025 | 0 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 May 2025 | Announcement | NuCana Prices $7 Million Registered Direct Offering |
| 06 May 2025 | Announcement | NuCana Prices $7 Million Registered Direct Offering |
| 20 Mar 2025 | Announcement | NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update |
| 20 Mar 2025 | Announcement | NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |